1-[4-[(4-fluorobenzoyl)amino]cyclohexyl]amine | 380829-13-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[4-[(4-fluorobenzoyl)amino]cyclohexyl]amine
• 英文别名: N-(4-aminocyclohexyl)-4-fluorobenzamide
• CAS: 380829-13-0
• 化学式: C₁₃H₁₇FN₂O
• mdl: MFCD12106855
• 分子量: 236.289
• InChiKey: TXEBCWVHHRLNBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND THEIR USE<br/>[FR] MODULATEURS DU RÉCEPTEUR X2 DE LA PROTÉINE G LIÉE AU MAS ET PRODUITS APPARENTÉS ET LEUR UTILISATION
  申请人：ESCIENT PHARMACEUTICALS INC

  公开号：WO2022087083A1

  公开（公告）日：2022-04-28

  Methods are provided for modulating MRGPRX2 or a MRGPRX2 ortholog generally, or for treating a MRGPRX2 or a MRGPRX2 ortholog dependent condition more specifically, by contacting the MRGPRX2 or the MRGPRX2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R1, R2, R3, R4, R5, R6and Rxare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

  本发明提供了调节MRGPRX2或MRGPRX2同源物的方法，或更具体地治疗MRGPRX2或MRGPRX2同源物依赖性疾病的方法，通过向需要的受体中注射具有结构（I）的化合物或其药学上可接受的盐、异构体、水合物、溶剂化物或同位素的有效剂量，其中W、Z、R1、R2、R3、R4、R5、R6和Rx的定义如本文所述。本发明还提供了包含这些化合物的制药组合物，以及这些化合物本身。
• [EN] MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS<br/>[FR] MODULATEURS DU RÉCEPTEUR MRGPRX2 ET PRODUITS ET PROCÉDÉS ASSOCIÉS
  申请人：ESCIENT PHARMACEUTICALS INC

  公开号：WO2022125636A1

  公开（公告）日：2022-06-16

  Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): (I) or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein D, W, Z, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

  本文提供了一种调节MRGPRX2的方法，或更具体地，用化合物(I)的结构或其药学上可接受的盐、异构体、水合物、溶剂化物或同位素的有效量接触MRGPRX2或对需要该方法的受试者进行治疗，以治疗MRGPRX2依赖性疾病。其中，D、W、Z、R1、R2和R3的定义如本文所述。同时，本文还提供了含有这些化合物的制药组合物以及化合物本身。
• [EN] MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS<br/>[FR] MODULATEURS DU RÉCEPTEUR X2 DE PROTÉINE G LIÉE À MAS, PRODUITS ET PROCÉDÉS ASSOCIÉS
  申请人：ESCIENT PHARMACEUTICALS INC

  公开号：WO2022140520A1

  公开（公告）日：2022-06-30

  Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein A, B, C, D, E, G, W, Y, Z, R1, R2, R3, R4, R5, R6, R7and R8are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

  本文提供了一种调节MRGPRX2的方法，或者更具体地治疗MRGPRX2依赖症状的方法，包括通过接触MRGPRX2或向需要接受治疗的受试者施用具有结构（I）的化合物或其药学上可接受的盐、异构体、水合物、溶剂化物或同位素的有效量，其中A、B、C、D、E、G、W、Y、Z、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。还提供了含有这样的化合物的药物组合物，以及这些化合物本身。
• Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV
  申请人：——

  公开号：US20020193390A1

  公开（公告）日：2002-12-19

  The present invention relates to certain N-(substituted glycyl)-2-cyanopyrrolidines of formula I 1 wherein Y is as defined herein, in free form or in acid addition salt form. Compounds of formula I inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceuticals in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance.

  本发明涉及某些 N-(取代的甘氨酰)-2-氰基吡咯烷，其式为 I 1 其中 Y 如本文所定义，以游离形式或酸加成盐形式存在。式 I 的化合物可抑制 DPP-IV（二肽基肽酶-IV）的活性。因此，它们可用作抑制 DPP-IV 和治疗由 DPP-IV 介导的疾病的药物，如非胰岛素依赖型糖尿病、关节炎、肥胖症、骨质疏松症和其他糖耐量受损疾病。
• 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS
  申请人：Novartis AG

  公开号：EP1296974A2

  公开（公告）日：2003-04-02